Prognostic Significance of Serum Inflammatory Response Markers in Newly Diagnosed Non-Small Cell Lung Cancer before Chemoirradiation.
OBJECTIVE
To identify whether the serum's baseline C-reactive protein (CRP) and albumin (Alb) levels related to clinicopathological parameters and overall survival (OS) in non-small cell lung cancer (NSCLC).


METHODS
In total, 100 consecutive patients (mean age = 68.38 ± 10.85 years) that underwent chemoradiotherapy were studied. Measurements of CRP and Alb were performed before any treatment.


RESULTS
Serum CRP levels were significantly associated with histological grade (P < 0.001), TNM stage (P < 0.001), PS (P = 0.009), and Alb (P < 0.001). Additionally CRP and Alb levels were found significantly associated with overall survival in univariate analysis (log-rank test, P < 0.001 and P = 0.002, resp.) and CRP remained significant after controlling for age, alcohol, performance status, and TNM stage, whereas albumin showed a borderline effect on the hazard rate (P = 0.052).


CONCLUSIONS
CRP and Alb are both promising biomarkers in identification of NSCLC patients with poor prognosis and form a possible target for intensifying their therapies.
Radiation Therapy Oncology Unit, Second Department of Radiology, University Hospital of Athens "ATTIKON", Rimini 1, Haidari, 124 64 Athens, Greece.
Maria
M
Tolia
Oncology Clinic, 401 General Military Hospital, Mesogeion 138 & Katehaki, 115 25 Athens, Greece.
Nikolaos
N
Tsoukalas
Department of Radiotherapy, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, 41110 Larissa, Greece.
George
G
Kyrgias
Radiation Therapy Oncology Unit, Second Department of Radiology, University Hospital of Athens "ATTIKON", Rimini 1, Haidari, 124 64 Athens, Greece.
Eftychia
E
Mosa
Pammakaristos General Hospital, Iakovaton 43, 11144 Athens, Greece.
Apostolos
A
Maras
Radiation Therapy Oncology Department, First Department of Radiology, Aretaieion Hospital, University of Athens Medical School, Vassilissis Sofias 76, 115 28 Athens, Greece.
Ioannis
I
Kokakis
Radiation Therapy Oncology Department, First Department of Radiology, Aretaieion Hospital, University of Athens Medical School, Vassilissis Sofias 76, 115 28 Athens, Greece.
Zoi
Z
Liakouli
Radiation Therapy Oncology Department, First Department of Radiology, Aretaieion Hospital, University of Athens Medical School, Vassilissis Sofias 76, 115 28 Athens, Greece.
John R
JR
Kouvaris
Biochemistry Department, 401 General Military Hospital, Mesogeion 138 & Katehaki, 115 25 Athens, Greece.
Konstantinos
K
Liaskonis
Oncology Clinic, University Hospital of Athens "ATTIKON", Rimini 1, Haidari, 124 64 Athens, Greece.
Nikolaos
N
Charalampakis
Radiation Oncology Clinic, University Hospital of Thessaloniki AHEPA, 1 Street Kyriakidi, 54636 Thessaloniki, Greece.
Kyriaki
K
Pistevou-Gombaki
Radiation Therapy Oncology Unit, Second Department of Radiology, University Hospital of Athens "ATTIKON", Rimini 1, Haidari, 124 64 Athens, Greece.
Nikolaos
N
Kelekis
Radiation Therapy Oncology Unit, Second Department of Radiology, University Hospital of Athens "ATTIKON", Rimini 1, Haidari, 124 64 Athens, Greece.
Vassilis
V
Kouloulias
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002097:C-Reactive Protein / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D049109:Cell Proliferation / Q000187:drug effects / Q000528:radiation effects; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D020266:Radiotherapy, Conformal; D012709:Serum Albumin / Q000378:metabolism*
D014408:Biomarkers, Tumor; D012709:Serum Albumin; D002097:C-Reactive Protein